Vericel Corp. (NASDAQ:VCEL)’s share price rose 6% on Friday . The stock traded as high as $2.43 and last traded at $2.28, with a volume of 280,052 shares trading hands. The stock had previously closed at $2.15.

Several equities research analysts recently commented on the stock. Bank of America Corp. lowered shares of Vericel Corp. from a “buy” rating to a “neutral” rating in a report on Tuesday, April 5th. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price target on shares of Vericel Corp. in a report on Tuesday, April 5th.

The company’s market capitalization is $51.17 million. The company has a 50 day moving average of $2.22 and a 200 day moving average of $2.77.

Vericel Corp. (NASDAQ:VCEL) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.17. The business earned $14.10 million during the quarter, compared to analyst estimates of $11.60 million. On average, equities research analysts expect that Vericel Corp. will post ($0.79) earnings per share for the current year.

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.